Development of inhibitors of Ubc13 and USP7 and assessment of their impact on cancer cell signaling

Ubc13 和 USP7 抑制剂的开发及其对癌细胞信号传导的影响评估

• 批准号: 366582
• 负责人: Glover J. N. Mark
• 金额: $ 7.29万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-11-01 至 2017-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=366582&lang=en
• 关键词: Dna Damage Signaling,; Lys63 Polyubiquitination; Nf-Kb Signaling; Protein Ubiquitination; Rational Drug Design; Structural Biology; Ubc13; Usp7; X-Ray Crystallography

Cancer cells are distinguished from normal cells by their ability to grow and survive under conditions where normal cells cannot. The aberrant survival of cancer cells appears to be due to the activation of natural systems within cells that help all cells

癌细胞与正常细胞的区别在于它们能够在正常细胞不能的条件下生长和存活。癌细胞的异常存活似乎是由于细胞内帮助所有细胞的自然系统的激活